Morgan Stanley Serves as Placement Agent on $750MM Credit Facility for BridgeBio Pharma
BridgeBio Pharma, a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, executed a definitive credit facility agreement with a syndicate of lenders for up to $750 million in financing. Morgan Stanley acted as the sole placement agent to BridgeBio on this transaction.
November 19, 2021
Andrew Lo | Brian Stephenson | BridgeBio Pharma | Latham & Watkins | Morgan Stanley
Ian Koplin